Affimed (NASDAQ:AFMD) will be issuing its quarterly earnings data before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
Affimed (NASDAQ:AFMD) last released its quarterly earnings data on Wednesday, May 22nd. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.19. Affimed had a negative return on equity of 23.61% and a negative net margin of 29.04%. The company had revenue of $12.89 million during the quarter, compared to the consensus estimate of $6.77 million. On average, analysts expect Affimed to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ AFMD traded down $0.01 during trading hours on Tuesday, hitting $2.68. The company’s stock had a trading volume of 36,927 shares, compared to its average volume of 691,952. Affimed has a 12 month low of $1.40 and a 12 month high of $7.35. The stock has a 50 day moving average price of $3.01. The company has a market capitalization of $184.68 million, a P/E ratio of -7.05 and a beta of 2.84. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.16 and a current ratio of 3.17.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Further Reading: What are the most popular ETFs
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.